Etihad Cargo - Reports
Latest Issue
Get instant access to latest e-book

LATEST NEWSRead more...

25

Jan 2021

Menarini obtains European Commission approval for the use of ELZONRIS (tagraxofusp) in the treatment of plasmacetoid blast dendritic cell neoplasm (NCDPB)

The Menarini Group a privatelyheld Italian pharmaceutical and diagnostic company announced that it has been granted marketing authorization by the European Commission for ELZONRIS tagraxofusp as a monotherapy for the firstline treatment of adult patients with plasmacytoid blast dendritic cell neopla...

22

Jan 2021

Servier and MiNA Therapeutics Enter Collaboration in Neurological Diseases

Servier a global and independent pharmaceutical Group and MiNA Therapeutics the pioneer in RNA activation therapeutics announced today a research partnership to identify and develop small activating RNA saRNA therapies for the treatment of neurological disorders

22

Jan 2021

Mitsubishi Tanabe Pharma America and Aquestive Therapeutics Announce U.S. Licensing and Supply Deal for Riluzole Oral Film for ALS Treatment

Mitsubishi Tanabe Pharma America Inc MTPA and Aquestive Therapeutics Inc announced a licensing and supply deal for the US rights to commercialize EXSERVAN riluzole an oral film formulation of riluzole for the treatment of amyotrophic lateral sclerosis ALS

21

Jan 2021

Nexelis acquires the GSK vaccines clinical bioanalytical laboratory located in Marburg - Germany and enters into a 5-year strategic agreement with GSK

Nexelis a portfolio company of Ampersand Capital Partners and a leading provider of advanced assay development and laboratory testing services in the infectious oncologic and metabolic diseases fields

press releasesRead more...

25

Jan 2021

FDA Grants Toripalimab Fast Track Designation for Mucosal Melanoma

Junshi Biosciences an innovationdriven biopharmaceutical company dedicated to the discovery development and commercialization of novel therapies announced that US Food and Drug Administration FDA has granted toripalimab Fast Track designation for the firstline treatment of mucosal melanoma

25

Jan 2021

European Commission Approves BAVENCIO® (avelumab) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma

EMD Serono the Healthcare business sector of Merck KGaA Darmstadt Germany in the US and Canada and Pfizer Inc today announced that the European Commission EC has approved BAVENCIO avelumab

25

Jan 2021

Roche renews partnership with Sysmex to deliver haematology testing solutions

Roche today announced that on December it signed a Global Business Partnership Agreement GBP with Sysmex Under this new framework the parties renewed their commitment to the long standing Distribution

25

Jan 2021

Quercis Pharma Licenses Key Patents for Thromboembolism Platform Across Cancer and COVID-19 Indications

Quercis Pharma AG a private clinical stage biopharmaceutical company leveraging its novel antithrombotic platform announced that it has entered into an exclusive worldwide license agreement for two patents with Beth Israel Deaconess Medical Center BIDMC

EventsRead more...

25 - 26

Jan 2021

25 - 26

Jan 2021

TOP ARTICLES

  • 3

    Personalised Therapy

    Drugs can be formulated in the form of tablets pellets emulsion cream and many others for patient consumption...

KNOWLEDGE BANK

  • Interviews

    Datamonitor

    Analyst

    include the changing patent laws as countries aim to become more TRIPS compliant with India updating its law recently and China in the process of doing so through the WTO Increasing globalization of the generics market with Indian companies becoming involved in Europe and the US and vice versa will also provide an opportunity for generics companies
  • Articles

    Endocrine Disrupting Compounds (EDCs)

    The accessibility of sufficient pure water in terms of both quantity and quality is vital for human existence Unfortunately our hydric resources have become seriously polluted due to the continuous expansion of industries and urbanisation

  • Techno Trends

    AXS-12 Novel Therapy Discovered for the Treatment of Narcolepsy

    Axsome Therapeutics Inc discovered AXS novel therapy for the treatment of cataplexy in patients with narcolepsy AXS is an oral highly selective and potent norepinephrine reuptake inhibitor AXS developed for cataplexy highlights its potential and provides meaningful benefit and substantial improvement for patients over currently available treatment

  • White Papers

    Tablet Coating at Low Bed Temperatures with a Novel Coating Polymer

    Currently when coating tablets with moisture sensitive actives aqueous film coatings based on PEG PVA and HPMC are recommended to be applied at high product temperatures to overcome the APIs sensitivity Unfortunately this approach can lead to heat degradation of the API and other potential physical tablet coating defects

EDITORIAL SECTION

  • EXPERT Talk

    PHARMA LOGISTICS TRENDS

    Pharma logistics is undergoing profound change throughout Asia as the ageing population drives a growing need for new pharma solutions together with s...